Alerts in the last 24 hours

No Personalised Alerts!

To see personalised alerts you need to be logged in.

Log In

GlaxoSmithKline PLC Add to portfolio

LON100:GSK, Oct 23, 08:06 UTC

Latest LON100:GSK News

Filter your feed

Apply Filter

Yesterday


News

Why FTSE 100 growth stock NMC Health could trash the GSK share price

GSK NMC

Why FTSE 100 growth stock NMC Health could trash the GSK share price. The share price of Abu Dhabi-based healthcare centre operator NMC Health (LSE: NMC) rose by 5% in early trading this morning after the firm said that its 2018 profits would be higher than expected. Full-year revenue is now expected to rise by 24%, up from previous guidance of 22%. And full-year earnings before interest, tax, depreciation and amortisation (EBITDA) are now expected to be $480m, 3.2% above previous guidance of $465m. It’s good news for shareholders, who’ve seen the value of their stock fall by more than 25% from August’s all-time high of 4,376p. But NMC shares aren’t cheap.

Read Full Details

Topics:
  • Business
  • Health
  • Financial
News

GSK Pharma: GSK Pharma Q2 profit down 23% to Rs 101 cr, Health News, ET HealthWorld

GSK

New Delhi: GlaxoSmithKline (GSK)Pharmaceuticals Monday reported 22.67 per cent fall in standalone net profit to Rs 100.77 crore for the quarter ended September 30, 2018. The company had posted a net profit of Rs 130.32 crore in the year-ago period, GSK Pharma said in a BSE filing. Total income of the company stood at Rs 831.13 crore for the reported quarter. Shares of GSK Pharma were trading at Rs 1,379.30 per scrip on BSE, down 3.11 per cent from the previous close.

Read Full Details

Topics:
  • Business
  • Financial

Sunday, October 21


News

DGAP-News: MorphoSys's Licensing Partner GSK has Reported Data on GSK3196165 from Phase 2 Study in Rheumatoid Arthritis to be Presented at the ACR Conference

GSK

MorphoSys AG (FSE: MOR; Prime Standard Segment, MDAX & TecDAX; NASDAQ: MOR) announced today that, in a press release issued today, its licensing partner GSK reported data from their phase 2 BAROQUE clinical study of GSK3196165 (formerly MOR103) in rheumatoid arthritis (RA). The data will be presented at the American College of Rheumatology (ACR) Annual Meeting on Monday, October 22, 2018, in Chicago, Illinois/USA, in the session "4M106 ACR Abstract: RA-Treatments III: New Compounds & Biosimilars (1935-1940)", to be held from 4:30-6:00pm Chicago Time (CDT). GSK3196165 is an investigational human monoclonal antibody directed against GM-CSF (granulocyte-macrophage colony-stimulating factor) that was outlicensed to GSK in 2013. Among the factors that may result in differences are that MorphoSys' expectations regarding the phase 2 development of GSK3196165 may be false, the inherent uncertainties associated with competitive developments, clinical trial and product development activities and regulatory approval requirements, MorphoSys' reliance on collaborations with third parties and other risks indicated in the risk factors included in MorphoSys's Registration Statement on Form F-1 and other filings with the US Securities and Exchange Commission may be incorrect.

Read Full Details

Topics:
  • Business
  • Health
  • Financial

Saturday, October 20


News

GSK picks WPP for global Panadol creative, digital and PR accounts

GSK WPP

WPP’s Grey Group was the incumbent for the creative account while Havas and Edelman held the digital and PR roles.Under the new deal, WPP will be responsible for Panadol’s global creative campaigns and content along with the brand’s PR and communications. GSK handed its own $1.5bn global media account to Publicis two weeks ago, in what was described as an ‘ugly and disrespectful’ process that saw WPP’s Mindshare lose the Asia Pacific work. Michael Duffy, global business lead for Panadol, GSK Consumer Healthcare, said: “Through the pitch process we were looking for an agency offering with real end-to-end capabilities and strong creative excellence to help us take Panadol to the next level and WPP really stepped up to the brief. CEO of WPP, Mark Read, added: “Panadol is a great brand and we are delighted to have been given the opportunity to use our creativity, data and technology to drive its growth around the world.

Read Full Details

Topics:
  • Business
  • Financial
  • Science

Friday, October 19


News

Forget cash ISAs! Why bother when you can get 5.5% a year from investing in the GSK share price

GSK

Why bother when you can get 5.5% a year from investing in the GSK share price. Here’s a sobering fact for savers: more than a decade after the financial crisis the average cash ISA still pays just 0.88%. And here’s a couple more: last year 10.8m people nonetheless put a mind-boggling £39.8bn into the tax-free savings vehicle. So much money, so little return. You can claim yields of more than 5% a year by investing in some of the UK’s biggest and best-known companies, such as pharmaceutical giant GlaxoSmithKline(LSE: GSK), which has long been one of the most generous dividend income payers on the FTSE 100. Companies fund these regular shareholder payouts from their earnings, and if those earnings drop or profits fall for any other reason, they are free to stop them (which doesn’t do much for the share price either).

Read Full Details

Topics:
  • Business
  • Health
  • Financial

Thursday, October 18


News

Better Buy: GlaxoSmithKline plc vs. Eli Lilly

GSK LLY +1 more GSK LLY GSK

In unsettled times in the market or the economy, investors often look to the big drug stocks for some safety. Investors like both stocks for their dividends and consistent performance, but the companies are really quite different, with GlaxoSmithKline diversified into vaccines and consumer products, and Eli Lilly focused on pharmaceuticals. The run-up in Lilly's stock price this year reflects the fact that the market has rewarded the stock with a higher valuation due to the strong performance of its business, so it's not surprising that Glaxo stock looks like the better bargain on the surface. At today's exchange rate between the dollar and the British pound, Glaxo's annual dividend works out to be $2.11, for a yield of 5.4%. Some dividend investors will prefer the higher yield, but the picture for dividend growth is another matter.

Read Full Details

Topics:
  • Business
  • Health
  • Financial
News

United States Influenza Vaccines Market to 2025 with Seqirus, Sanofi Pasteur, GlaxoSmithKline (GSK) and AstraZeneca Set to Dominate

SAN GSK +3 more SAN GSK GSK AZN AZN

A comprehensive analysis has been done on pricing, distribution & demand and effectiveness of influenza vaccines in the United States. Additionally, the report includes an assessment of clinical trials, promising influenza vaccines in clinical development and rapid diagnostic testing for the management of influenza. Other emerging players such as Novavax, Daiichi-Sankyo, Mitsubishi TanabePharma and Biondvax Pharmaceuticals Ltd, are making novel technology-based influenza vaccines which are likely to affect the market share during the forecast period.The major companies dominating this market for its products, services and continuous product developments are Seqirus, Sanofi Pasteur, GlaxoSmithKline (GSK) and AstraZeneca.Data Included. At what pace is the influenza vaccines market growing in United States? What will be the growth trend in future? How many people are being vaccinated with influenza vaccines during 2013 - 2025? What are the key drivers and inhibitors in the current market? What will be the impact of drivers and inhibitors in the future? What are the various influenza vaccines available in the United States? How is the market predicted to develop in the future?

Read Full Details

Topics:
  • Business
  • Health

Wednesday, October 17


News

JPMorgan Chase & Co. Reiterates Overweight Rating for Redrow (RDW) – Fairfield Current

GSK JPM +2 more GSK JPM GSK RDW

Redrow (LON:RDW)‘s stock had its “overweight” rating restated by analysts at JPMorgan Chase & Co. in a research report issued to clients and investors on Tuesday, September 25th. Finally, Barclays raised their price objective on Redrow from GBX 658 ($8.60) to GBX 693 ($9.06) and gave the stock an “equal weight” rating in a report on Wednesday, September 12th. Four analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. Redrow has a 52-week low of GBX 488 ($6.38) and a 52-week high of GBX 673.50 ($8.80).

Read Full Details

Topics:
  • Business
  • Financial
  • Health

Monday, October 15


News

+$96 Billion Opportunity for the Global Precision Medicine Market by 2023 - Featuring Abbott Labs, GE, GSK, Pfizer, J&J, Novartis, and more - ResearchAndMarkets.com

ABT GSK +2 more ABT GSK GE PFE

+$96 Billion Opportunity for the Global Precision Medicine Market by 2023 - Featuring Abbott Labs, GE, GSK, Pfizer, J&J, Novartis, and more - ResearchAndMarkets.com. DUBLIN--(BUSINESS WIRE)--The "Global Precision Medicine Market (2018-2023)" report has been added to ResearchAndMarkets.com's offering. The global precision medicine market is expected to have a significant compounded annual growth rate (CAGR) of 9.7% and have a market size in excess of USD 96 Bn by 2023. North America dominates the global market due to the high incidence of cancer and increasing government initiatives in the region. The global precision medicine market is classified into three primary segments - based on end use: pharmaceuticals and biotech companies, clinical laboratories, diagnostic companies and healthcare IT specialists/big data companies; based on therapeutics: cancer, cardiovascular, central nervous system, psychiatric disorder and infectious diseases; and based on sub-market: big data analytics, bioinformatics, gene sequencing, pharmacogenomics and companion diagnostics.

Read Full Details

Topics:
  • Business
  • Health
  • Science

Friday, October 12


News

GlaxoSmithKline (GSK) Rating Increased to Buy at Zacks Investment Research – PressOracle

GSK GSK

Meanwhile, a strong start to its three newest products — Trelegy Ellipta, Shingrix and Juluca — and buy in of Novartis’ stake in the Consumer Healthcare JV have strengthened Glaxo’s competitive position. Glaxo’s shares have outperformed the broader industry this year. However, pricing pressure and competitive dynamics are hurting sales of Glaxo’s inhaled respiratory products, particularly the older ones. One research analyst has rated the stock with a sell rating, ten have given a hold rating and seven have issued a buy rating to the company’s stock. In other GlaxoSmithKline news, major shareholder Plc Glaxosmithkline purchased 80,000 shares of the business’s stock in a transaction dated Tuesday, July 17th.

Read Full Details

Topics:
  • Business
  • Financial